PMC:7047369 / 8892-9783 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"115","span":{"begin":209,"end":214},"obj":"Species"},{"id":"121","span":{"begin":479,"end":489},"obj":"Chemical"},{"id":"122","span":{"begin":504,"end":514},"obj":"Chemical"},{"id":"123","span":{"begin":516,"end":525},"obj":"Chemical"},{"id":"124","span":{"begin":558,"end":577},"obj":"Chemical"},{"id":"125","span":{"begin":647,"end":658},"obj":"Chemical"}],"attributes":[{"id":"A115","pred":"tao:has_database_id","subj":"115","obj":"Tax:9606"},{"id":"A121","pred":"tao:has_database_id","subj":"121","obj":"MESH:D009705"},{"id":"A122","pred":"tao:has_database_id","subj":"122","obj":"MESH:C000606551"},{"id":"A123","pred":"tao:has_database_id","subj":"123","obj":"MESH:D012254"},{"id":"A124","pred":"tao:has_database_id","subj":"124","obj":"MESH:C558899"},{"id":"A125","pred":"tao:has_database_id","subj":"125","obj":"MESH:D002738"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"What is in the pipeline for vaccine development and/or therapeutics?\nIt appears that no vaccine will be available for at least one year, likely a little longer. Phase 1 trials for safety and immunogenicity in human populations are likely within 3 months.\nIn terms of therapeutics there is no known effective pharmaceutical agent. There are over 200 registered clinical trials registered in China alone. Putative agents include antivirals; Griffithsin, a spike protein inhibitor, nucleoside analogues eg. remdesivir, ribavirin and protease inhibitors such as lopinavir/ritonavir. Immunomodulatory and other host targeted agents include interferon, chloroquine and immunoglobulins. Corticosteroids will potentially have benefit for immune mediated lung damage late in the course of disease [6]. Much of the theory stems from what we have learnt from limited trials in other corona viruses [7]."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T142","span":{"begin":468,"end":477},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T141","span":{"begin":479,"end":489},"obj":"CHEBI:60783;CHEBI:60783"},{"id":"T140","span":{"begin":504,"end":514},"obj":"DG_28"},{"id":"T139","span":{"begin":516,"end":525},"obj":"DG_29"},{"id":"T138","span":{"begin":558,"end":567},"obj":"DG_23;CHEBI:31781;CHEBI:31781"},{"id":"T137","span":{"begin":568,"end":577},"obj":"DG_30"},{"id":"T136","span":{"begin":647,"end":658},"obj":"CHEBI:3638;DG_10;CHEBI:3638"},{"id":"T135","span":{"begin":680,"end":695},"obj":"CHEBI:50858;CHEBI:50858"},{"id":"T134","span":{"begin":730,"end":736},"obj":"UBERON:0002405"},{"id":"T133","span":{"begin":746,"end":750},"obj":"UBERON:0002048"},{"id":"T132","span":{"begin":872,"end":878},"obj":"NCBITaxon:11118"},{"id":"T131","span":{"begin":879,"end":886},"obj":"NCBITaxon:10239"},{"id":"T145","span":{"begin":191,"end":205},"obj":"BV_15"},{"id":"T144","span":{"begin":209,"end":214},"obj":"SP_6;NCBITaxon:9606"},{"id":"T143","span":{"begin":308,"end":328},"obj":"CHEBI:52217;CHEBI:52217"}],"text":"What is in the pipeline for vaccine development and/or therapeutics?\nIt appears that no vaccine will be available for at least one year, likely a little longer. Phase 1 trials for safety and immunogenicity in human populations are likely within 3 months.\nIn terms of therapeutics there is no known effective pharmaceutical agent. There are over 200 registered clinical trials registered in China alone. Putative agents include antivirals; Griffithsin, a spike protein inhibitor, nucleoside analogues eg. remdesivir, ribavirin and protease inhibitors such as lopinavir/ritonavir. Immunomodulatory and other host targeted agents include interferon, chloroquine and immunoglobulins. Corticosteroids will potentially have benefit for immune mediated lung damage late in the course of disease [6]. Much of the theory stems from what we have learnt from limited trials in other corona viruses [7]."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T7","span":{"begin":460,"end":467},"obj":"Body_part"},{"id":"T8","span":{"begin":663,"end":678},"obj":"Body_part"},{"id":"T9","span":{"begin":746,"end":750},"obj":"Body_part"}],"attributes":[{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A8","pred":"fma_id","subj":"T8","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A9","pred":"fma_id","subj":"T9","obj":"http://purl.org/sig/ont/fma/fma7195"}],"text":"What is in the pipeline for vaccine development and/or therapeutics?\nIt appears that no vaccine will be available for at least one year, likely a little longer. Phase 1 trials for safety and immunogenicity in human populations are likely within 3 months.\nIn terms of therapeutics there is no known effective pharmaceutical agent. There are over 200 registered clinical trials registered in China alone. Putative agents include antivirals; Griffithsin, a spike protein inhibitor, nucleoside analogues eg. remdesivir, ribavirin and protease inhibitors such as lopinavir/ritonavir. Immunomodulatory and other host targeted agents include interferon, chloroquine and immunoglobulins. Corticosteroids will potentially have benefit for immune mediated lung damage late in the course of disease [6]. Much of the theory stems from what we have learnt from limited trials in other corona viruses [7]."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T6","span":{"begin":746,"end":750},"obj":"Body_part"}],"attributes":[{"id":"A6","pred":"uberon_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"What is in the pipeline for vaccine development and/or therapeutics?\nIt appears that no vaccine will be available for at least one year, likely a little longer. Phase 1 trials for safety and immunogenicity in human populations are likely within 3 months.\nIn terms of therapeutics there is no known effective pharmaceutical agent. There are over 200 registered clinical trials registered in China alone. Putative agents include antivirals; Griffithsin, a spike protein inhibitor, nucleoside analogues eg. remdesivir, ribavirin and protease inhibitors such as lopinavir/ritonavir. Immunomodulatory and other host targeted agents include interferon, chloroquine and immunoglobulins. Corticosteroids will potentially have benefit for immune mediated lung damage late in the course of disease [6]. Much of the theory stems from what we have learnt from limited trials in other corona viruses [7]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T56","span":{"begin":144,"end":145},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T57","span":{"begin":209,"end":214},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T58","span":{"begin":452,"end":453},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T59","span":{"begin":746,"end":750},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T60","span":{"begin":746,"end":750},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T61","span":{"begin":879,"end":886},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"}],"text":"What is in the pipeline for vaccine development and/or therapeutics?\nIt appears that no vaccine will be available for at least one year, likely a little longer. Phase 1 trials for safety and immunogenicity in human populations are likely within 3 months.\nIn terms of therapeutics there is no known effective pharmaceutical agent. There are over 200 registered clinical trials registered in China alone. Putative agents include antivirals; Griffithsin, a spike protein inhibitor, nucleoside analogues eg. remdesivir, ribavirin and protease inhibitors such as lopinavir/ritonavir. Immunomodulatory and other host targeted agents include interferon, chloroquine and immunoglobulins. Corticosteroids will potentially have benefit for immune mediated lung damage late in the course of disease [6]. Much of the theory stems from what we have learnt from limited trials in other corona viruses [7]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T6","span":{"begin":308,"end":322},"obj":"Chemical"},{"id":"T7","span":{"begin":427,"end":437},"obj":"Chemical"},{"id":"T8","span":{"begin":460,"end":467},"obj":"Chemical"},{"id":"T9","span":{"begin":468,"end":477},"obj":"Chemical"},{"id":"T10","span":{"begin":479,"end":499},"obj":"Chemical"},{"id":"T11","span":{"begin":479,"end":489},"obj":"Chemical"},{"id":"T12","span":{"begin":504,"end":514},"obj":"Chemical"},{"id":"T13","span":{"begin":516,"end":525},"obj":"Chemical"},{"id":"T14","span":{"begin":530,"end":549},"obj":"Chemical"},{"id":"T16","span":{"begin":539,"end":549},"obj":"Chemical"},{"id":"T17","span":{"begin":558,"end":577},"obj":"Chemical"},{"id":"T18","span":{"begin":558,"end":567},"obj":"Chemical"},{"id":"T19","span":{"begin":568,"end":577},"obj":"Chemical"},{"id":"T20","span":{"begin":635,"end":645},"obj":"Chemical"},{"id":"T21","span":{"begin":647,"end":658},"obj":"Chemical"},{"id":"T22","span":{"begin":872,"end":878},"obj":"Chemical"}],"attributes":[{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_52217"},{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A8","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A9","pred":"chebi_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A10","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_60783"},{"id":"A11","pred":"chebi_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_33838"},{"id":"A12","pred":"chebi_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"},{"id":"A13","pred":"chebi_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/CHEBI_63580"},{"id":"A14","pred":"chebi_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/CHEBI_37670"},{"id":"A15","pred":"chebi_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/CHEBI_60258"},{"id":"A16","pred":"chebi_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A17","pred":"chebi_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A18","pred":"chebi_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A19","pred":"chebi_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A20","pred":"chebi_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A21","pred":"chebi_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A22","pred":"chebi_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/CHEBI_37409"}],"text":"What is in the pipeline for vaccine development and/or therapeutics?\nIt appears that no vaccine will be available for at least one year, likely a little longer. Phase 1 trials for safety and immunogenicity in human populations are likely within 3 months.\nIn terms of therapeutics there is no known effective pharmaceutical agent. There are over 200 registered clinical trials registered in China alone. Putative agents include antivirals; Griffithsin, a spike protein inhibitor, nucleoside analogues eg. remdesivir, ribavirin and protease inhibitors such as lopinavir/ritonavir. Immunomodulatory and other host targeted agents include interferon, chloroquine and immunoglobulins. Corticosteroids will potentially have benefit for immune mediated lung damage late in the course of disease [6]. Much of the theory stems from what we have learnt from limited trials in other corona viruses [7]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T64","span":{"begin":0,"end":68},"obj":"Sentence"},{"id":"T65","span":{"begin":69,"end":160},"obj":"Sentence"},{"id":"T66","span":{"begin":161,"end":254},"obj":"Sentence"},{"id":"T67","span":{"begin":255,"end":329},"obj":"Sentence"},{"id":"T68","span":{"begin":330,"end":402},"obj":"Sentence"},{"id":"T69","span":{"begin":403,"end":578},"obj":"Sentence"},{"id":"T70","span":{"begin":579,"end":679},"obj":"Sentence"},{"id":"T71","span":{"begin":680,"end":792},"obj":"Sentence"},{"id":"T72","span":{"begin":793,"end":891},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"What is in the pipeline for vaccine development and/or therapeutics?\nIt appears that no vaccine will be available for at least one year, likely a little longer. Phase 1 trials for safety and immunogenicity in human populations are likely within 3 months.\nIn terms of therapeutics there is no known effective pharmaceutical agent. There are over 200 registered clinical trials registered in China alone. Putative agents include antivirals; Griffithsin, a spike protein inhibitor, nucleoside analogues eg. remdesivir, ribavirin and protease inhibitors such as lopinavir/ritonavir. Immunomodulatory and other host targeted agents include interferon, chloroquine and immunoglobulins. Corticosteroids will potentially have benefit for immune mediated lung damage late in the course of disease [6]. Much of the theory stems from what we have learnt from limited trials in other corona viruses [7]."}